IMARC Group's report titled "Pharmacovigilance Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032", The global pharmacovigilance market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/pharmacovigilance-market/requestsample

Factors Affecting the Growth of the Pharmacovigilance Industry:

• Technological Advancements:

Technology enables the collection of vast amounts of data from various sources, including electronic health records (EHRs), social media, wearable devices, and healthcare databases. This wealth of data provides a more comprehensive understanding of drug safety profiles and allows for early detection of adverse events. Advanced data processing techniques, such as big data analytics and natural language processing (NLP), help in mining, organizing, and analyzing these data sets efficiently.

• Increasing Patient Awareness and Reporting:

As patients are becoming more informed about their healthcare and medication use, they play a crucial role in reporting adverse drug reactions (ADRs) directly to regulatory agencies, healthcare providers, or through online platforms. This results in a larger pool of data on drug safety, providing pharmacovigilance professionals with valuable insights into the real-world usage and potential risks associated with medications.

• Rising Drug Approval Rates:

With rising drug approval rates, there is a steady influx of new medications entering the market. Each newly approved drug requires comprehensive pharmacovigilance monitoring throughout its lifecycle to ensure ongoing assessment of safety and efficacy. The growing number of approved drugs expands the scope and complexity of pharmacovigilance activities, driving the demand for pharmacovigilance services and expertise.

Leading Companies Operating in the Global Pharmacovigilance Industry:

• Accenture plc
• ArisGlobal LLC
• BioClinica Inc. (Cinven Partners LLP)
• Capgemini
• Cognizant
• International Business Machines Corporation
• ICON plc.
• IQVIA Inc.
• ITClinical
• Parexel International Corporation and Wipro Limited.

Explore full report with table of contents: https://www.imarcgroup.com/pharmacovigilance-market

Pharmacovigilance Market Report Segmentation:

By Service Provider:

• In-house
• Contract Outsourcing

Contract outsourcing represents the largest segment due to the reliance of pharmaceutical companies on specialized service providers to manage pharmacovigilance activities, allowing them to focus on core operations while leveraging external expertise and cost efficiencies.

By Product Life Cycle:

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV
   

Phase IV accounts for the majority of the market share as post-market surveillance becomes increasingly critical for monitoring drug safety and effectiveness in real-world settings, ensuring compliance with regulatory requirements and addressing emerging safety concerns post-approval.

By Type:

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Spontaneous reporting exhibits a clear dominance in the market owing to its rising utilization in collecting adverse event data, leveraging healthcare professionals, patients, and other stakeholders to report adverse reactions voluntarily.

By Process Flow:

• Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing and Reporting
• Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review and Reporting
• Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Signal detection holds the biggest market share driven by its pivotal role in identifying potential safety concerns by analyzing pharmacovigilance data to detect statistical associations between drugs and adverse events, enabling proactive risk management and regulatory compliance.

By Therapeutic Area:

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Oncology dominates the market, with escalating demand for robust pharmacovigilance strategies to monitor the safety profiles of anticancer drugs and manage unique safety challenges associated with oncology treatments.

By End Use:

• Pharmaceuticals Companies
• Biotechnology Companies
• Medical Device Companies
• Others

Pharmaceutical companies represent the largest segment, which can be attributed to their crucial role in developing, manufacturing, and marketing drugs, necessitating comprehensive pharmacovigilance programs to ensure drug safety and regulatory compliance throughout the product lifecycle.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the pharmacovigilance market on account of its well-established regulatory framework, advanced healthcare infrastructure, high pharmaceutical expenditure, and presence of major pharmaceutical companies.

Global Pharmacovigilance Market Trends:

Pharmaceutical companies are increasingly outsourcing pharmacovigilance activities to specialized service providers and contract research organizations (CROs) to streamline operations, reduce costs, and leverage specialized expertise. This trend is driving the growth of the outsourcing segment. Additionally, there's a growing focus on using real-world data sources, such as electronic health records (EHRs), claims databases, and wearable devices, to generate real-world evidence for pharmacovigilance. This approach enhances regulatory decision-making and supports post-market surveillance efforts.

Furthermore, patient engagement and patient-reported outcomes are becoming more important in pharmacovigilance. Initiatives aimed at empowering patients to report adverse events are improving medication safety and incorporating patient perspectives into regulatory decision-making processes, ensuring more comprehensive and patient-centered pharmacovigilance practices.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163